Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, insulin-infusion device specialist Insulet (NAS: PODD) has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Insulet's business and see what CAPS investors are saying about the stock right now.
Bedford, Mass. (2000)
CEO Duane DeSisto (since 2003)
Return on Equity (average, past 3 years)
$94.0 million / $108.5 million
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 37% of the 107 members who have rated Insulet believe the stock will underperform the S&P 500 going forward.
The future in this space belongs to the company that can make and market "The Artificial Pancreas", the device that simultaneously measures changes in glucose and reponds with an immediate and correct insulin dosage. [Insulet's] problem is that it's up against heavy-weights and [outgunned] by their marketeers. I cannot see it getting bought out. It will, I fear, slip and stagnate.
If you want to retire rich, you need to protect your portfolio from any undue risk. Luckily, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap with big potential. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow theTrackPoisedToCAPS account.
At the time thisarticle was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.